Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wet AMD AND Age-Related Macular Degeneration

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Wet AMD AND Age-Related Macular Degeneration. Displaying page 6 of 6.
    « Previous 1  2  3  4  5  6 
    EudraCT Number: 2022-000214-34 Sponsor Protocol Number: SYL1801_II Start Date*: 2022-10-08
    Sponsor Name:SYLENTIS S.A.U
    Full Title: A Randomized, Double masked, Parallel group, Dose-finding study to evaluate SYL1801 in patients with neovascular AMD
    Medical condition: Wet form of Neovascular Age-Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10075568 Wet age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-002431-15 Sponsor Protocol Number: CRFB002ADE23 Start Date*: 2013-10-09
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 12-month, phase IV, randomized, open label, multicenter study to compare efficacy of 0.5 mg ranibizumab PRN compared to 2 mg aflibercept bimonthly intravitreal injections on retinal thickness sta...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001058-73 Sponsor Protocol Number: BEY-RAP.V1.0 Start Date*: 2021-06-23
    Sponsor Name:Fakultní nemocnice Královské Vinohrady
    Full Title: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation - Prospective Randomised Study
    Medical condition: Retinal angiomatous proliferation form of neovascular age related macular degeneration (AMD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004959-39 Sponsor Protocol Number: CRFB002A2405 Start Date*: 2013-05-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional a...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) GR (Completed) SE (Completed) FI (Completed) PT (Completed) HU (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-004172-12 Sponsor Protocol Number: CBPD952A2309 Start Date*: 2007-01-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with Lucentis™ versus Luc...
    Medical condition: Subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) BE (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002626-23 Sponsor Protocol Number: CRFB002A2411 Start Date*: 2013-11-26
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen,...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) BE (Completed) DE (Completed) SK (Completed) GB (Completed) HU (Completed) PT (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001085-10 Sponsor Protocol Number: CRFB002AGB17 Start Date*: 2014-09-08
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A phase IV, prospective, open label, uncontrolled, European study in patients with neovascular age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching from intravit...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 07:09:01 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA